Abstract
Allogeneic stem cell transplantation is a potentially curative therapy for some malignant
and non-malignant disease. There have been substantial advances since the approaches
first introduced in the 1970s, and the development of approaches to transplant with
HLA incompatible or alternative donors has improved access to transplant for those
without a fully matched donor. However, success is still limited by morbidity and
mortality from toxicity and imperfect disease control. Here we review our emerging
understanding of how reconstitution of effective immunity after allogeneic transplant
can protect from these events and improve outcomes. We provide perspective on milestones
of immune reconstitution that are easily measured and modifiable.
Keywords
Abbreviations:
ADCC (Antibody dependent cellular cytotoxicity), CBT (Umbilical cord blood transplant), CLPs (Common lymphoid progenitors), CRFS (Chronic GvHD Relapse Free Survival), DFS (Disease Free Survival), GvHD (Graft versus Host Disease), HCT (Allogeneic hematopoietic stem cell transplant), HPCSs (Hematopoietic progenitor cells), IR (Immune Reconstitution), NRM (Non-relapse mortality), OS (Overall Survival), PTCy (Post-Transplant Cyclophosphamide), TRM (Treatment related mortality), TCD (T cell depleted)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources.Expert Rev Clin Immunol. 2019; 15: 735-751
- Age-dependent incidence, time course, and consequences of thymic renewal in adults.Journal of Clinical Investigation. 2005; 115: 930-939
- AGE, THYMOPOIESIS, AND CD4+ T-LYMPHOCYTE REGENERATION AFTER INTENSIVE CHEMOTHERAPY.New England Journal of Medicine. 1995; 332: 143-149
- Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution.Blood. 2016; 128: 2607-2615
- Immune reconstitution following stem cell transplantation.Hematology Am Soc Hematol Educ Program. 2015; 2015: 215-219
- The mechanism of action of cyclosporin A and FK506.Immunol Today. 1992; 13: 136-142
- Immunosuppressive drugs: the first 50 years and a glance forward.Immunopharmacology. 2000; 47: 63-83
- GVHD Prophylaxis 2020.Front Immunol. 2021; 12605726
- Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016.Biol Blood Marrow Transplant. 2018; 24: 895-908
- Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.J Hematol Oncol. 2018; 11: 127
- Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.Ann Intern Med. 1986; 105: 20-26
- Early lymphocyte recovery post-allogeneic hematopoietic stem cell transplantation is associated with significant graft-versus-leukemia effect without increase in graft-versus-host disease in pediatric acute lymphoblastic leukemia.Bone Marrow Transplantation. 2008; 41: 245-252
- Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies.Biology of Blood and Marrow Transplantation. 2009; 15: 1108-1115
- Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.Biology of Blood and Marrow Transplantation. 2007; 13: 1216-1223
- An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT.Transplant Cell Ther. 2021; 27: 317-326
- Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT).Biol Blood Marrow Transplant. 2008; 14: 1022-1030
- How I vaccinate blood and marrow transplant recipients.Blood. 2016; 127: 2824-2832
- 2017 ECIL 7 vaccine guidelines.Lancet Infect Dis. 2019; 19: 694-695
- Casting a wider protective net: Anti-infective vaccine strategies for patients with hematologic malignancy and blood and marrow transplantation.Blood Rev. 2020; 100779
- Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.Transplant Cell Ther. 2021; 27: 788-794
- Serologic Responses following a Single Dose of SARS-Cov-2 Vaccination in Allogeneic Stem Cell Transplantation Recipients.Transplant Cell Ther. 2021; 27 (880.e1-880.e4)
- Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant.JAMA Netw Open. 2021; 4e2126344
- Live (vaccines) from New York.Bone Marrow Transplant. 2013; 48: 749-754
- Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.Leuk Lymphoma. 2017; 58: 1859-1871
- SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.Blood. 2018; 132: 1737-1749
- Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).Biol Blood Marrow Transplant. 2019; 25: 2143-2151
- Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation.Br J Haematol. 2004; 125: 217-224
- Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation.Biol Blood Marrow Transplant. 2007; 13: 1216-1223
- Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies.Biol Blood Marrow Transplant. 2009; 15: 1108-1115
- Early lymphocyte reconstitution is associated with improved transplant outcome after cord blood transplantation.Cytotherapy. 2011; 13: 78-82
- Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.Leukemia. 2007; 21: 2145-2152
- Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.Blood. 2015; 125: 3173-3182
- Early Natural Killer Cell Reconstitution Predicts Overall Survival in T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2016; 22: 2187-2193
- Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome.Biol Blood Marrow Transplant. 2018; 24: 1841-1847
- Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus.MMWR Suppl. 1989; 38: 1-9
- HIV-1 Associated Opportunistic Infections, in StatPearls.StatPearls Publishing, 2020 (Copyright © 2020, StatPearls Publishing LLC.: Treasure Island (FL))
- Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions.Blood. 1999; 93: 467-480
- Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34(+) Selected Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2017; 23: 1759-1766
- Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome.Transplantation. 2002; 74: 1551-1559
- Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality.Bone Marrow Transplant. 2008; 41: 55-62
- Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation.Bone Marrow Transplant. 2006; 37: 1119-1128
- The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation.Blood Transfus. 2012; 10: 174-180
- Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.Lancet Haematol. 2015; 2: e194-e203
- Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation.Cytotherapy. 2020; 22: 503-510
- Anti-Thymocyte Globulin Exposure in CD34+ T Cell Depleted Allogeneic Hematopoietic Cell Transplantation.Lancet pre-prints. 2021;
- CD4+ T-cell reconstitution predicts Survival Outcomes after acute Graft-versus-Host-Disease; a dual center validation.Blood. 2020;
- Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation.J Allergy Clin Immunol. 2017; 140 (e9): 1643-1650
- Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism.Blood. 2000; 95: 352-359
- Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation.Nat Med. 2013; 19: 372-377
- Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.Bone Marrow Transplant. 2015; 50: 1227-1234
- Quantitative tracking of T cell clones after haematopoietic stem cell transplantation.EMBO Mol Med. 2011; 3: 201-207
- CDR3 and V genes show distinct reconstitution patterns in T cell repertoire post-allogeneic bone marrow transplantation.Immunogenetics. 2021; 73: 163-173
- T Cell Clonal Dynamics Determined by High-Resolution TCR-β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2020; 26: 1567-1574
- The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment.Semin Immunopathol. 2021; 43: 101-117
- Effect of Graft-versus-Host Disease Prophylaxis Regimens on T and B Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2019; 25: 1260-1268
- Evaluating Thymic Function After Human Hematopoietic Stem Cell Transplantation in the Personalized Medicine Era.Front Immunol. 2020; 11: 1341
- T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/βTREC ratio and thymic naive T cells.Haematologica. 2013; 98: 1600-1608
- Clinical significance of T cell receptor excision circle (TREC) quantitation after allogenic HSCT.Blood Res. 2019; 54: 274-281
- Thymic activity in immune recovery after allogeneic hematopoietic stem cell transplantation in children.Cent Eur J Immunol. 2020; 45: 151-159
- Immune reconstitution in patients with Fanconi anemia after allogeneic bone marrow transplantation.Cytotherapy. 2014; 16: 976-989
- High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.Bone Marrow Transplant. 1997; 20: 909-913
- Plasma concentration monitoring of busulfan: does it improve clinical outcome?.Clin Pharmacokinet. 2000; 39: 155-165
- Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.Lancet Haematol. 2016; 3: e526-e536
- Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan.J Oncol Pharm Pract. 2021; 27: 579-587
- Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes.Blood Adv. 2019; 3: 2179-2187
- Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34(+) Selected Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2019; 25: 1526-1535
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.J Clin Oncol. 2017; 35: 4003-4011
- Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation.Blood Adv. 2018; 2: 565-574
- Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.Cancer Chemother Pharmacol. 2020; 86: 711-717
- Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.Blood. 2007; 110: 4543-4551
- Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.Biol Blood Marrow Transplant. 2012; 18: 565-574
- Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2016; 22: 1636-1645
- Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.Biol Blood Marrow Transplant. 2006; 12: 734-748
- Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome.Blood. 2014; 123: 126-132
- Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.Blood Adv. 2020; 4: 191-202
- Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation.Blood. 2016; 128: 2734-2741
- Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft.Expert Opin Biol Ther. 2008; 8: 583-597
- Cord Blood Units with High CD3(+) Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell-Depleted Single Cord Blood Transplantation.Biol Blood Marrow Transplant. 2016; 22: 1073-1079
- Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation.Front Immunol. 2020; 11: 1068
- High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Oncotarget. 2016; 7: 27255-27266
- Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide.Ann Hematol. 2020; 99: 1341-1350
- Transplantation of megadoses of purified haploidentical stem cells.Ann N Y Acad Sci. 1999; 872 (discussion 361-2): 351-361
- Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back.Br J Haematol. 2001; 115: 95-104
- Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells.Ann N Y Acad Sci. 2005; 1044: 70-83
- Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemia.Blood. 2018; 132: 2594-2607
- Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients.Transplant Cell Ther. 2021; 27 (169.e1-169.e9)
- αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies.Blood Adv. 2021; 5: 240-249
- NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.Blood. 2018; 131: 247-262
- Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.Sci Transl Med. 2013; 5 (p. 211ra157)
- Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide.Blood Adv. 2021; 5: 352-364
- Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.Blood. 2015; 125: 2855-2864
- Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation.Blood. 2015; 125: 2865-2874
- Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Biol Blood Marrow Transplant. 2020; 26: 1915-1922
- Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.Biol Blood Marrow Transplant. 2018; 24: 1022-1028
- Sex steroid ablation: an immunoregenerative strategy for immunocompromised patients.Bone Marrow Transplant. 2015; 50 (Suppl 2): S77-S81
- Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy.Bone Marrow Transplant. 2019; 54: 749-755
- Human proT-cells generated in vitro facilitate hematopoietic stem cell-derived T-lymphopoiesis in vivo and restore thymic architecture.Blood. 2013; 122: 4210-4219
- Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation.Journal of Molecular Medicine-Jmm. 2007; 85: 837-843
- Age-associated loss of bone marrow hematopoietic cells is reversed by GH and accompanies thymic reconstitution.Endocrinology. 2002; 143: 690-699
- Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation.Blood. 2010; 115: 1088-1097
- Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation.Transplantation. 2003; 75: 1977-1983
- Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets.J Exp Med. 2008; 205: 1701-1714
- CD3(+)/CD19(+) Depleted Matched and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplant with Targeted T Cell Addback Is Associated with Excellent Outcomes in Pediatric Patients with Nonmalignant Hematologic Disorders.Biol Blood Marrow Transplant. 2019; 25: 549-555
- Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation.Cytotherapy. 2005; 7: 116-125
- Hodgkin's lymphoma relapsing after autologous transplantation: allogeneic hematopoietic stem cell transplantation using a strategy of reduced intensity conditioning, and T-cell depletion with T-cell add-back.Eur J Haematol. 2009; 83: 273-275
- T cell depletion utilizing CD34(+) stem cell selection and CD3(+) addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients.Br J Haematol. 2012; 157: 205-219
- Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.Bone Marrow Transplant. 2016; 51: 1217-1222
- Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders.Int J Cancer. 2019; 144: 1135-1146
- CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.Front Immunol. 2018; 9: 3016
- Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells.Cytotherapy. 2018; 20: 532-542
- Optimizing a photoallodepletion protocol for adoptive immunotherapy after haploidentical SCT.Bone Marrow Transplant. 2012; 47: 1196-1200
- Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of αβ T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia.Bone Marrow Transplant. 2021;
- T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation.Blood. 2012; 120: 1820-1830
- Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.Blood. 2015; 125: 4103-4113
- Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.Lancet Oncol. 2009; 10: 489-500
- Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant.Clin Transl Immunology. 2021; 10: e1249
- Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.N Engl J Med. 1995; 333: 1038-1044
- Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.Blood. 2009; 114: 4283-4292
- Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.Biol Blood Marrow Transplant. 2015; 21: 1663-1678
- Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.Blood. 1998; 92: 1549-1555
- Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.Blood. 2012; 119: 2644-2656
- Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2009; 15: 382-388
- CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.Sci Transl Med. 2010; 2 (41ra52)
- Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.Blood. 2011; 117: 1061-1070
- Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.Blood. 2016; 127: 1044-1051
- T cell receptor repertoires after adoptive transfer of expanded allogeneic regulatory T cells.Clin Exp Immunol. 2017; 187: 316-324
- Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.Blood. 2011; 117: 3921-3928
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.Blood. 2010; 115: 925-935
- Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses.Blood Adv. 2021; 5: 496-503
Article info
Publication history
Accepted:
September 18,
2021
Received:
June 21,
2021
Identification
Copyright
© 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
